Zyvox (linezolid; Pfizer) is the first antimicrobial agent from the oxazolidinone class to reach the market. The synthetic agent inhibits the early phase of bacterial protein synthesis. It binds to the bacterial 23S peptidyltransferase center of the 50S ribosomal subunit and subsequently inhibits the bacterial translation process by preventing the formation of the crucial 70S initiation complex. Zyvox has demonstrated activity against a range of clinically relevant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and penicillin-resistant pneumococci. The drug’s unique mechanism of action decreases the probability of cross-resistance with other classes of antibacterial agents.
The availability of a dual oral and intravenous formulation for Zyvox (linezolid; Pfizer), and the ability to switch patients easily between these two forms, have enhanced the drug’s clinical attractiveness in the management of susceptible bacterial pathogens, and enabled its progressive access to the major global markets. However, the adoption of Zyvox in the clinical management of community-acquired pneumonia (CAP) has been limited to more severe cases, especially those associated with the resistant Gram-positive bacteria methicillin-resistant Staphylococcus aureus (MRSA). The drug’s high price in comparison to its generically available competitors, such as vancomycin, has further limited its widespread use in the management of CAP. Datamonitor Healthcare believes that Teva’s launch of generic linezolid in the US market in February 2015 will deliver a strong blow to branded Zyvox in this market and will mark the start of severe generic erosion of Zyvox’s share in the CAP market.
6 Figure 1: Zyvox for community-acquired pneumonia – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Zyvox in communityacquired
8 Figure 3: Datamonitor Healthcare’s drug assessment summary of Zyvox in communityacquired
19 Figure 4: Zyvox – SWOT analysis in cSSSI
20 Figure 5: Datamonitor Healthcare’s drug assessment summary of Zyvox in cSSSI
20 Figure 6: Datamonitor Healthcare’s drug assessment summary for Zyvox in cSSSI
LIST OF TABLES
4 Table 1: Zyvox drug profile
14 Table 2: Zyvox’s drug profile in cSSSI
16 Table 3: Overview of pivotal trial data for Zyvox in cSSSI
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.